NCT00070499 2026-03-18
Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
17 trialsNCT00792948 2026-03-18
Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02143414 2026-03-18
Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02059265 2023-08-01
Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT04439305 2020-07-20
Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT00423735 2019-07-24
Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00459342 2019-03-05
Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01260688 2018-08-08
Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel
National Cancer Institute (NCI)
Phase 2 Completed
NCT00859937 2018-04-20
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00459108 2018-04-19
Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00563290 2015-06-18
Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00470054 2015-05-05
Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00474812 2015-05-05
Dasatinib in Treating Patients With Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00507767 2014-10-01
Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00504153 2014-05-19
Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00436605 2014-05-15
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00112775 2011-06-07
BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate
National Cancer Institute (NCI)
Phase 2 Unknown